洛铂联合重组白介素―2腹腔灌注治疗癌性腹水效果及安全性分析.docVIP

洛铂联合重组白介素―2腹腔灌注治疗癌性腹水效果及安全性分析 　　[摘要]目的 探讨洛铂联合重组白介素-2腹腔灌注治疗癌性腹水的效果及安全性。方法 选取2015年3月～2017年3月我院收治的34例癌性腹水患者作为研究对象，根据患者入院日期的单双数将其分为两组，每组各17例。对照组采用50 ml生理盐水、60～100 mg洛铂、10 mg地塞米松为患者实施腹腔灌注治疗，观察组采用50 ml生理盐水、60～100 mg洛铂、10 mg地塞米松以及100万U白介素-2为患者实施腹腔灌注治疗。比较两组患者的临床疗效、生活质量（KPS）评分情况及毒副作用发生情况。结果 两组患者的治疗总有效率比较，差异无统计学意义（P0.05）；观察组患者的KPS评分改善率高于对照组，降低率低于对照组，差异均有统计学意义（P0.05），两组患者的白细胞降低及骨髓抑制发生率较高，其他毒副作用发生率均较低。结论 洛铂联合重组白介素-2腹腔灌注治疗癌性腹水能够提升临床疗效，改善患者的生活品质。 　　[关键词]癌性腹水；洛铂；白介素-2 　　[中图分类号] R734.3 [文献标识码] A [文章编号] 1674-4721（2017）12（b）-0131-04 　　[Abstract]Objective To investigate the efficacy and safety analysis of Lobaplatin combined with Recombinant Interleukin-2 peritoneal injection for the treatment of malignant ascites.Methods 34 patients with malignant ascites from March 2015 to March 2017 treated in our hospital were selected as subjects，and they were divided into two groups according to the number of singular or double digits of the admission date ，17 cases in each group.The control group was treated with 50 ml of Physiological Saline，60～100 mg of Lobaplatin and 10 mg of Dexamethasone with peritoneal perfusion，the observation group was treated with 50 ml of Physiological Saline，60～100 mg of Lobaplatin，10 mg of Dexamethasone and 1 million U Interleukin-2 with peritoneal perfusion.The clinical efficacy，quality of life （KPS） scores and adverse effects of the two groups were compared.Results The total efficiency of treatment was compared between the two groups，and the difference was not statistically significant （P0.05）.The proportion of improvement of KPS score in the observation group was higher than that in the control group，and the proportion of decrease was lower than that in the control group，and the differences were statistically significant （P0.05），and the incidence of leukocyte reduction and bone marrow suppression were higher in both groups，and the incidence of other adverse effects were lower.Conclusion The treatment of malignant ascite with Lobaplatin combined with Recombin